Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First- and Second-Generation Antipsychotics for Children and Young Adults

Slide: 6 of 43

Introduction to Antipsychotics in Pediatric Use (4 of 4)

Prescribing of antipsychotics for children with mental and behavioral disorders continues to increase and includes off-label use. However, the effects of both first-generation (FGAs) and second-generation (SGAs) antipsychotics on patient-centered outcomes such as growth, development, and quality of life are not well understood. Studies of efficacy, benefits, and adverse effects of FGAs and SGAs used for pediatric treatment are reported in the clinical literature. The strength of the evidence (high, moderate, or low) found in the clinical literature does not necessarily equate with the U.S. Food and Drug Administration approval status.